WRBY
SellPremium GrowerWarby Parker Inc. · Healthcare · United States · $3.1B · Avg Vol: $57M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT WARBY PARKER INC.
Read
Warby Parker Inc. is a vertically integrated, omni-channel eyewear brand that designs and sells prescription glasses, sunglasses, and contact lenses, while also providing eye exams. The company's competitive moat is built on its direct-to-consumer model, which bypasses traditional optical licensing giants to offer premium products at accessible price points. It operates as a disruptive consumer brand leveraging a highly productive physical retail expansion strategy.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 598.1M | 669.8M | 771.3M | 871.9M | 13.4% | 911.6M | 971.1M | 1.1B | 14.2% |
| EPS | -0.96 | -0.54 | -0.17 | 0.01 | — | 0.06 | — | — | — |
| Shares | 115.3M | 118.2M | 120.8M | 122.4M | +6.2% | 108.2M | — | — | — |
| Debt | 173.4M | 174.5M | 225.4M | 233.1M | 10.4% | 251.0M | — | — | — |
| Equity | 286.6M | 301.8M | 340.1M | 367.7M | 8.7% | — | — | — | — |
| Op CF | 10.4M | 61.0M | 98.7M | 110.8M | 120.2% | 95.4M | — | — | — |
| Inv CF | -60.2M | -54.7M | -66.0M | -67.0M | — | — | — | — | — |
| Fin CF | 3.3M | 2.9M | 5.0M | -12.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WRBY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WRBY | Warby Parker Inc.(you) | $3.1B | 34 | Sell |
| PLSE | Pulse Biosciences, Inc. | $3.4B | 22 | Sell |
| MMED | MiniMed Group, Inc. | $5.7B | 40 | Hold |
| KMTS | Kestra Medical Technologies, Ltd. | $1.5B | 26 | Sell |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.